a
a
Weather:
No weather information available
HomeHealthFangzhou Launches Otsuka’s Third-Generation Leukemia Drug Ponatinib on its Platform

Fangzhou Launches Otsuka’s Third-Generation Leukemia Drug Ponatinib on its Platform

GUANGZHOU, China, May 5, 2025 /PRNewswire/ — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical’s third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online…

No comments

Sorry, the comment form is closed at this time.

Translate »